AUSTRALIAN PRODUCT RECALL

APO-Valsartan 40 mg / 80 mg / 160 mg / 320 mg tablets

Published 7 January 2019

Product

These valsartan-containing products are used to treat high blood pressure (also known as hypertension) and other heart-related disorders. APO-Valsartan 40 mg / 80 mg / 160 mg / 320 mg tablets APO-VALSARTAN valsartan 40 mg tablet blister pack All batches APO-VALSARTAN valsartan 80 mg tablet blister pack All batches APO-VALSARTAN valsartan 160 mg tablet blister pack All batches APO-VALSARTAN valsartan 320 mg tablet blister pack All batches

Why it was recalled

Trace amounts of an impurity, N nitrosodiisopropylamine (NDIPA), has been detected in batches of this product.

Hazard

N nitrosodiisopropylamine (NDIPA), is in the N nitroso chemical class that is known to contain mutagens and carcinogens (substances that could potentially cause cancer). However based on the information available to Apotex to date, the company has advised that it expects the health risk from use of affected APO-Valsartan tablets is very low.

Read the official notice ↗

Source: Based on ACCC data or other content. ACCC © Commonwealth of Australia. ACCC-owned material is licensed under CC BY 4.0. RecallMatch extracts and formats notice information for screening. Third-party material may have separate rights. Source and reuse terms. Verify details in the official notice. RecallMatch is independent of the ACCC.